Association between FSAP 1601G > A polymorphism and venous thromboembolism risk: A meta-analysis

Objective Previous several studies have shown that factor VII-activating protease (FSAP) gene 1601G>A polymorphism is related to the occurrence of venous thromboembolism, but the results are inconsistent and controversial. Therefore, we conducted a meta-analysis to explore the association between FSAP 1601G>A polymorphism and venous thromboembolism susceptibility. Methods We managed a systematic literature search through Pubmed, Embase, Web of Science, China National Knowledge Infrastructure, and WanFang databases to collect research data related to FSAP gene 1601G>A polymorphism and susceptibility to venous thromboembolism published before May 2019. Data analysis was performed through Revman 5.3 and Stata 12.0 software, the pooled odd ratios and 95% confidence intervals were calculated. Additionally, the sensitivity analysis and publication bias assessment were also performed. Results A total of seven case–control studies were included and evaluated, including 2411 venous thromboembolism cases and 2850 controls. The meta-analysis results revealed that the FSAP 1601G>A mutation is associated with venous thromboembolism risk, and statistically significance was observed under three genetic comparison models (A: G, odds ratio: 1.33, 95% confidence interval: 1.07–1.66; GA: GG, odds ratio: 1.34, 95% confidence interval: 1.06–1.68; and GA + AA: GG, odds ratio: 1.33, 95% confidence interval: 1.06–1.66). Conclusion This study demonstrated that the FSAP 1601G>A polymorphism may be associated with venous thromboembolism susceptibility.